基于网络药理学解析银黄颗粒对小鼠代谢相关脂肪性肝病的保护通路
本研究采用网络药理学预测银黄颗粒(YHG)改善代谢相关脂肪性肝病(MAFLD)的靶点,并在甲硫氨酸胆碱缺乏(MCD)饮食诱导6周的小鼠模型中验证。结果显示YHG可减轻肝细胞损伤与脂质蓄积、抑制肝星状细胞活化与肝纤维化,并通过Nrf2通路缓解氧化应激损伤。
要点
- 银黄颗粒在MCD诱导MAFLD小鼠中减轻肝细胞损伤与肝脏脂质蓄积。
- 银黄颗粒抑制肝星状细胞活化并减轻MCD喂养小鼠的肝纤维化。
- 银黄颗粒经Nrf2信号通路缓解MCD诱导的肝脏氧化应激损伤。
核心结论
- 银黄颗粒通过减少肝脏脂质蓄积、减轻肝脏氧化与炎症损伤及 attenuating 肝纤维化,改善MCD诱导的小鼠MAFLD。
研究设计与样本
- 研究采用网络药理学分析银黄颗粒改善MAFLD的潜在靶点,并以MCD饮食喂养6周诱导小鼠MAFLD模型。
- 模型小鼠在最后2周每日口服银黄颗粒400或800 mg/kg,检测血清与肝脏生化指标及肝脏基因表达。
主要发现
- 网络药理学显示银黄颗粒可改善MAFLD、炎症、肝纤维化与氧化应激。
- 动物实验中银黄颗粒减轻MCD诱导的肝细胞损伤与肝脏脂质蓄积。
- 银黄颗粒减轻MCD诱导的小鼠肝脏炎症,并抑制肝星状细胞活化、缓解肝纤维化。
- 银黄颗粒通过Nrf2信号通路缓解MCD诱导的小鼠肝脏氧化应激损伤。
临床怎么用
- 本结果来自小鼠MCD模型,提示银黄颗粒对MAFLD相关脂质蓄积、炎症、氧化损伤与纤维化的潜在作用,尚不能直接推导至临床用药。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Metabolic-associated fatty liver disease (MAFLD) is a spectrum of liver disorders. Nonalcoholic steatohepatitis (NASH) is defined as a more serious process of MAFLD with liver inflammation. PURPOSE: This study aims to observe the alleviation of Yinhuang granule (YHG), a Chinese patent medicine, on methionine and choline-deficient diet (MCD)-induced MAFLD in mice. METHODS: Network pharmacology was used to analyze the improving effect of YHG on MAFLD and possible targets. MAFLD was induced in mice by MCD diet feeding for 6 weeks. In the last 2 weeks, the mice were orally given with YHG (400, 800 mg/kg) every day. Biochemical parameters of serum and liver, as well as hepatic gene expression were detected. RESULTS: Network pharmacology showed that YHG could improve MAFLD, inflammation, liver fibrosis, and oxidative stress. In animal experiments, YHG reduced hepatocellular damage and hepatic lipids accumulation which induced by MCD. In terms of liver inflammation, YHG attenuated MCD-induced liver inflammation in mice. YHG also inhibited the activation of hepatic stellate cells (HSCs) and alleviated liver fibrosis in MCD-fed mice. Through nuclear factor erythroid 2-related factor 2 (Nrf2) signaling pathway, YHG alleviated liver oxidative stress injury in mice which induced by MCD. CONCLUSION: YHG ameliorated MCD-induced MAFLD in mice by reducing hepatic lipids accumulation, alleviating liver oxidative, inflammatory injury and attenuating hepatic fibrosis.
引用
- Yan S, Zhang S, Du A, et al. Network pharmacology-based identification of significant pathway for protection of Yinhuang granule in a mice model of metabolic-associated fatty liver disease. Phytomedicine. 2021. PMID: 34339944. doi:10.1016/j.phymed.2021.153666
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。